SS-31 (Elamipretide) Side Effects: Injection-Site Reactions, Allergy Warnings, and What to Report

The product this page covers:

At 2 mg/mL, 0.25 mL is 0.5 mg of SS-31 per dose (arithmetic from the vial strength, on a U-100 insulin syringe), and a vial holds 20 doses, about four weeks of weekday dosing. Your own directions are set by your physician after reviewing your intake and are printed on the vial. The price is all-in: medication, physician review, refill management and shipping, with no membership fee. SS-31 is compounded by a PCAB-accredited, FDA-registered US 503A pharmacy. Compounded medications are not FDA approved.

SS-31 is a four-amino-acid peptide that concentrates on the inner mitochondrial membrane, where it binds a lipid called cardiolipin. Under its generic name, elamipretide, it has been through randomised, double-blind, placebo-controlled trials in four diseases, at 40 mg subcutaneously daily, for four to 48 weeks, with open-label follow-up to 168 weeks in Barth syndrome. In September 2025 the FDA granted accelerated approval to a branded elamipretide product for Barth syndrome, a rare genetic disease. That gives SS-31 a larger human safety record than almost any other compounded peptide, and an approved label to read warnings from.

Two cautions apply to every number on this page:

• The trials used 40 mg daily. The typical printed direction for the compounded vial delivers 0.5 mg on weekdays, a small fraction of that. Side-effect rates measured at the trial dose may not apply at a much lower dose, in either direction, and no study has measured them at the compounded dose.
• The trials enrolled people with diagnosed diseases. There is no safety database in healthy adults.

What the trials recorded

Injection-site reactions are frequent, usually mild, and the main reason people stop. Notice the placebo figures: two thirds of people on a dummy injection in TAZPOWER had a local reaction, and 71% on placebo in ReCLAIM-2 reported some adverse event. A daily needle and a volume of fluid cause reactions on their own.

Reducing them

SS-31 is injected under the skin, into the fat layer, usually in the abdomen or outer thigh, rotating sites. The Monday-through-Friday schedule is a prescriber convention that rests the injection sites; the trials all dosed every day. A small lump that appears as you inject and softens over a day or two is fluid in the tissue. One that appears days later and is warm, spreading or more painful each day is different and needs a same-day message. Technique is in how to inject peptides safely.

The approved elamipretide label warns of hypersensitivity reactions, including serious allergic reactions. Pepti's general side-effect guide notes that the approved label describes hypersensitivity reactions that required emergency intervention and could appear anywhere from minutes to months after starting. That timing matters: a reaction is not ruled out because the first few weeks went smoothly.

Signs to act on: hives beyond the injection site, swelling of the face, lips, tongue or throat, throat tightness, difficulty breathing, or faintness. Call 911 first. Tell your care team afterwards, because the reaction goes on your record and changes what can be prescribed to you again.

• Safety in healthy adults. Every randomised trial enrolled people with a diagnosed disease.
• Side effects at the compounded dose. The trials used 40 mg daily; nobody has measured what happens at 0.5 mg on weekdays.
• Interactions. There is no formal interaction list, which is why a physician reviews every medication you take.
• Very long-term use. The longest follow-up is a small Barth syndrome group for more than three years.

No withdrawal, rebound or dependency is described anywhere in the literature, and the peptide is cleared within hours.

Elamipretide is not on the FDA's Category 2 list of substances flagged for significant safety risk and never has been. Since September 2025 it has been a component of an FDA-approved drug, which makes it eligible for 503A compounding without a bulks-list entry, subject to the FDA's "essentially a copy" rule. The approved product is an 80 mg/mL solution given as 40 mg daily for Barth syndrome; the compounded vial is a different strength, prepared to an individual prescription, and not FDA approved. If you have Barth syndrome, the approved product through a specialist is the right path.

• site reactions that are getting worse over weeks rather than settling
• itching or hives anywhere other than the injection site
• you are diagnosed with kidney disease, or told your kidney function has fallen
• you start any new medication
• you become pregnant or plan to

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

All three get called mitochondrial treatments, and their side-effect profiles differ. MOTS-c has no human safety trial; what is reported is mostly injection-site reactions and some transient jitteriness after a morning dose. NAD+ produces flushing, chest tightness, nausea and site stinging when it goes in quickly. SS-31 has the largest human safety record of the three, dominated by injection-site reactions. No trial has tested any combination. The wider category is in peptides for energy and fatigue.

Elamipretide's side-effect profile is measured, not inferred: several randomised, placebo-controlled trials, hundreds of participants, up to a year of treatment, and more than three years of follow-up in a small group. It is consistent: injection-site reactions dominate, systemic effects are similar to placebo, and the approved label's serious warning is hypersensitivity. The limits are equally clear. Those trials used 40 mg daily in people with diseases, and the compounded vial is prescribed at a small fraction of that dose for uses the trials did not test. The rates on this page describe the molecule at the trial dose, not the vial at the compounded dose. The general picture is in peptide side effects: what to watch for.

SS-31 cannot be bought legitimately without a prescription. Products sold "for research use only" have no accountable pharmacy behind their identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications, allergies and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance, and prescribes SS-31 in every state except Oklahoma, plus DC The step-by-step page is how to get SS-31 prescribed online.